Table 2 Objective 1 outcomes and measures
Outcome | Measure | Method |
|---|---|---|
Primary outcome | ||
 Healthcare-associated infection (HAI) rates in each trial site | Numbers of Staphylococcus aureus bacteraemia (SAB), Clostridium difficile infection (CDI) and clinical isolates of vancomycin resistant enterococci (VRE) and monthly rates per 10,000 occupied bed days | Datasets include all patients across the hospital with a HAI, and data on occupied bed days Collated from: - Hospital infection data and reports for ongoing surveillance - Hospital occupied bed days reports |
Secondary outcome | ||
 Hospital cleaning performance—thoroughness of hospital cleaning in each trial site | Number and percentage of ultraviolet (UV) gel dots removed completely following cleaning | DAZO® Fluorescent Marking Gel dots applied to frequent touch sites around two patient cubicle and bathroom areas in the intensive care unit (ICU) and the highest risk wards |
Other outcomes—study specific data set | ||
 Bio-burden of frequent touch surfaces post cleaning | Levels of organic matter in relative light units (RLUs) post cleaning in three hospitals | Adenosine tri-phosphate (ATP) bioluminescence measurements |
Other outcomes—study specific data set | ||
 Changes in staff knowledge and attitudes around environmental cleaning | Pre-intervention educational needs. Pre- and post-intervention knowledge and attitudes about environmental cleaning and job roles | Environmental services staff questionnaires and discussion groups |
Other outcomes—existing data set | ||
 Changes in rates of screening and clinical isolates | Numbers of positive clinical isolates of other multi-resistant organisms per 1000 patient days at risk | Collated from hospital infection data and reports, where available for ongoing surveillance and supplied to project team by trial site team |
Other outcomes—existing data set | ||
 Changes in patients’ perception of hospital cleanliness | Patients’ perceptions of cleanliness | Collated from existing hospital-based survey data, where available and supplied to project team by trial site team |